Supernus Pharmaceuticals, Inc. (SUPN)
$42.01-1.87%Close
BUYRECOVERY · day 49
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.4B
- Beta
- 0.55
- P/E (TTM)
- -21.86
- Short % float
- 9.16%
- Days to cover
- 7.4
- SI change
- -0.1%
- 1W
- -1.91%
- 1M
- +1.25%
- vs SPY 1W
- -1.78%
- vs SPY 1M
- -1.25%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$13.6BRECOVERYQ 16$135.13-4.41%
- JAZZSELLJazz Pharmaceuticals plc$13.2BBEARQ 24$210.39-2.93%
- AXSMSELLAxsome Therapeutics, Inc.$8.0BCRISISQ 34$156.32-5.83%
- IONSSELLIonis Pharmaceuticals, Inc.$7.0BCRISISQ 8$42.38-2.95%
- PRAXSELLPraxis Precision Medicines, Inc.$6.8BCRISISQ 11$243.34-3.20%
- XENESELLXenon Pharmaceuticals Inc.$3.3BCRISISQ 22$34.42-3.88%
- ACADSELLAcadia Pharmaceuticals Inc.$3.2BCRISISQ 17$18.62-4.07%
- DNLISELLDenali Therapeutics Inc.$2.9BCRISISQ 8$18.40-2.90%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SUPN?
- LOPJLB’s latest quantitative signal on Supernus Pharmaceuticals, Inc. (SUPN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is SUPN in?
- Supernus Pharmaceuticals, Inc. (SUPN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Supernus Pharmaceuticals, Inc. (SUPN) do?
- Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release …